[en] Adhesion molecules such as CD44 play an important role in the metastatic cascade by mediating tumor cell interaction with the endothelium and the subendothelial matrix. As a so-called "lymphocyte homing receptor," CD44 is physiologically involved in migration of circulating lymphocytes to lymphatic tissue. In the present study, we investigated the expression of CD44v3 and v6 in 237 patients with stage IB, N0 cervical carcinoma by means of immunohistochemistry. These results were correlated with the GOG score and other prognostic variables. Median follow-up was 82.6 months (39-110 months). Thirty-nine patients recurred and 35 died from disease within the observation period. In univariate analysis, the GOG score, histologic subtype, and CD44v6 expression were statistically significant predictors for poor overall survival (OS). In multivariate (Cox regression) analysis, the GOG score (< 40 vs. 40-120, RR: 1.37 (95% CI: 1.10-1.71); 40-120 vs. > 120, RR: 2.23 (95% CI: 1.28-3.88); P = 0.004), histologic subtype (adenosquamous carcinomas) (RR: 4.56 (95% CI: 1.49-13.92), P = 0.007) and CD44v6 expression (RR: 2.42 (95% CI: 1.14-5.10), P = 0.021) were independent predictors for poor OS. The expression of CD44v3 did not correlate with prognosis. Furthermore we found a strong correlation between CD44v6 expression and lymphovascular space invasion (LVSI) (chi2 = 17.01, P = 0.0001). Tumor expansion into the loco-regional lymphatic system is the preferred way of tumor spread in cervical carcinoma. The strong correlation of CD44v6 with LVSI produces a significant degree of suspicion that cervical carcinoma cells expressing CD44v6 could, by mimicking lymphocytes, exploit their pathways.
Disciplines :
Reproductive medicine (gynecology, andrology, obstetrics)
Author, co-author :
Speiser, P.
KRIDELKA, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > Gynécologie-Obstétrique
Tempfer, C.
Edwards, L.
Leodolter, S.
Kainz, C.
Hacker, N. F.
Language :
English
Title :
CD44v6 expression is an independent prognostic factor in node-negative FIGO stage IB cervical carcinoma.
Publication date :
1999
Journal title :
International Journal of Gynecological Cancer
ISSN :
1048-891X
eISSN :
1525-1438
Publisher :
Blackwell Science, Malden, United States - Massachusetts
Guenthert U, Hofmann M, Rudy W et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991;65:13-24.
Matsumura Y, Tarin D. Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 1992;340:1053-8.
Jalkanen S, Steere A, Fox R, Butcher E. A distinct endothelial cell recognition system that controls lymphocyte traffic into inflamed synovium. Science 1986;233:556-8.
Salles G, Zain M, Jiang W, Boussiotis V, Shipp M. Alternatively spliced CD44 transcripts in diffuse large cell lymphomas: characterisation and comparison with normal activated B cells and epithelial malignancies. Blood 1993;82:3539-47.
Jalkanen S, Bargatze R, de los Toyos J, Butcher E. Lymphocyte recognition of high endothelium: antibodies to distinct epitopes of an 85-95 kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells. J Cell Biol 1987;105:983-90.
Inagaki H, Suzuki T, Nomoto K, Yosihakai Y. Increased susceptibility to primary infection with Listeria monocytogenes in germ-free mice may be due to lack of accumulation of l-selectin+CD 44+ T cells in sites of inflammation. Infect Immun 1996;64:3280-7.
Dali P, Heider KH, Hekele A et al. Surface protein expression and messenger RNA-splicing analysis of CD44 in uterine cervical cancer and normal epithelium. Cancer Res 1994;54:3337-41.
Dall P, Hekele A, Ikenberg H et al. Increasing incidence of CD44v7/8 epitope expression during uterine cervical carcinogenesis. Int J Cancer 1996;69:79-85.
Kohlberger P, Kieback DG, Bancher D et al. Immunohistochemical detection of CD44 splice variant expression in premalignant lesions of the cervix and benign cervical epithelium. Gynecol Oncol 1997;66:227-31.
Dellas A, Schultheiss E, Almendral AC, Torhost J, Gudat F. Expression of CD44 and variant isoforms in cervical intraepithelial neoplasia. Gynecol Oncol 1996;62:218-25.
Shimabukuro K, Toyamo-Sorimachi N, Ozaki Y et al. The expression patterns of standard and variant CD44 molecules in normal uterine cervix and cervical carcinoma. Gynecol Oncol 1997;64:26-34.
Kainz C, Kohlberger P, Tempfer C, Sliutz G, Gitsch G. Prognostic value of CD44 splice variants in human cervical cancer stage III. Eur J Cancer 1995;31:1706-9.
Kainz C, Kohlberger P, Sliutz G et al. Splice variants of CD44 in human cervical cancer stage IB to IIB. Gynecol Oncol 1995;57:383-7.
Speiser P, Wanner C, Tempfer C et al. CD44 is an independent prognostic factor in early stage cervical cancer. Int J Cancer 1997;74:185-8.
Delgado G, Bundy B, Zaino R, Sevin B, Creasman WT, Major F. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1990;38:352-7.
Wielenga VJM, Heider KH, Offerhaus JA et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression.. Cancer Res 1993;53: 4754-6.
Combaret V, Gross N, Lasset C et al. Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. J Clin Oncol 1996;14:25-34.
Look KY, Brunette VL, Clarke-Pearson DL et al. An analysis of cell type in patients with surgically staged stage IB carcinoma of the cervix: A Gynecologic Oncology Group Study. Gynecol Oncol 1996;63:304-11.
Arch R, Wirth K, Hofmann M et al. Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science 1992;257:682-5.
Herrlich P, Zoeller M, Pals S, Ponta H. CD44 splice variants: metastases meets lymphocytes, Immunol Today 1993;14:395-9.
Culty M, Nguyen HA, Underhill CB. The hyaluronan receptor (CD44) participates in the uptake and degradation of hyaluronan. J Cell Biol 1992;116:1055-62.